Working… Menu

Blood Glucose Response to Highly Viscous Polysaccharide Enriched Biscuits in Healthy and Diabetic Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00728143
Recruitment Status : Completed
First Posted : August 5, 2008
Last Update Posted : August 5, 2008
Information provided by:
Unity Health Toronto

Brief Summary:
Our objective was to test whether the highly viscous polysaccharide incorporated into the biscuit formulation would reduce the postprandial blood glucose response equally in healthy subjects and individuals with type 2 diabetes.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Dietary Supplement: Highly viscous polysaccharide enriched biscuits Not Applicable

Detailed Description:

Despite significant achievements in treatment modalities and preventive measures, diabetes has been increasing exponentially. Reduction in both fasting and prolonged postprandial glycemia is of paramount importance in the disease prevention and the delay of diabetic complications. Blood glucose concentration can be reduced by dietary means, and may be influenced by factors such as type and amount of carbohydrate, nature of starch, quantity of protein and fat, dietary fiber content, method of food processing, particle size and food form. Glycemic index (GI) is a measure of the blood glucose-raising ability of the available carbohydrate in foods. Although evidence is often insufficient and individual differences occur, prospective studies and clinical trials have shown that low-GI diets may reduce the risk of diabetes and improve glycemic control in diabetes.

High postprandial plasma glucose level can increase severity of diabetes and foods which raise the blood glucose level least for a given carbohydrate content are most suitable for individuals with type 2 diabetes. Lower postprandial glycemia is also important for healthy subjects to prevent diabetes.

High fiber diets have been recommended for the general population and for the nutritional management of patients with type 2 diabetes. Soluble dietary fiber retards digestion and absorption of the associated dietary carbohydrate, thus flattening the postprandial rise in plasma glucose and insulin concentrations. Some foods such as beta-glucan fiber containing oats and barley, and soluble fibers isolates such as pectin, guar, psyllium, or glucomannan have a high viscosity which gives them the greatest blood glucose lowering effect. Viscous fibers, as a result of their rheological properties, form gel with the food and human digesta and consequently reduce postprandial increases in plasma glucose concentrations in both normal and diabetic subjects in positive relation to their level of viscosity. Insoluble fibers such as cellulose and wheat bran have little effect.

The highly viscous polysaccharide (HVP) added to the study biscuit formulation is a blend of highly viscous soluble fibers (polysaccharides) that act synergistically to develop a higher level of viscosity than any other known dietary fiber in nature. One of the main components of the HVP is glucomannan, a glucose-mannose polysaccharide obtained from grinding the tuber root of Amorphophallus Konjac C. Koch, a plant that has been used as food and remedy for thousands of years in the Far East. Highly refined glucomannan is 3 times more viscous than guar and approximately 7 times more viscous than psyllium. The viscosity of the HVP is amplified further with a viscosity 3-5 times higher than glucomannan alone used in formulation, that is considered to be the highest viscosity single dietary fiber. Previously we and others have shown that the higher viscosity in vitro directly corresponded to lower blood glucose.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
Official Title: Therapeutic Trials of Low Glycemic Index Foods and Dietary Fiber in the Management of Diabetes, Hyperlipidemia and Renal Disease
Study Start Date : August 1989
Actual Primary Completion Date : November 1989
Actual Study Completion Date : November 1989

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: 1
Healthy subjects
Dietary Supplement: Highly viscous polysaccharide enriched biscuits
10 g of highly viscous polysaccharide
Other Name: HVP

Experimental: 2
Diabetic subjects
Dietary Supplement: Highly viscous polysaccharide enriched biscuits
10 g of highly viscous polysaccharide
Other Name: HVP

Primary Outcome Measures :
  1. Glycemic Index [ Time Frame: Two months ]

Secondary Outcome Measures :
  1. Palatability [ Time Frame: Two months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria (arm 1):

  • males or non-pregnant females aged 18-75 years and in good health;
  • BMI <30 kg/m2.

Exclusion Criteria (arm 1):

  • known history of hepatitis, diabetes or a heart condition;
  • using medications or fiber supplements;
  • any health condition which might affect the results;
  • non-compliance with the experimental procedures.

Inclusion Criteria (arm 2):

  • documented type 2 diabetes for at least 6 month duration without clinically manifest complications;
  • age 18-75 years;
  • BMI <30 kg/m2.

Exclusion Criteria (arm 2):

  • liver or kidney disease;
  • gastrointestinal problems;
  • using fiber supplements;
  • non-compliance with the experimental procedures;
  • pregnancy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00728143

Sponsors and Collaborators
Unity Health Toronto
Layout table for investigator information
Principal Investigator: David Jenkins, MD, PhD, DSc Unity Health Toronto
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Director of Research, Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital Identifier: NCT00728143    
Other Study ID Numbers: 1_Jenkins
First Posted: August 5, 2008    Key Record Dates
Last Update Posted: August 5, 2008
Last Verified: August 2008